SCHEMBL4390141

SCHEMBL4390141

NC(O)[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)C(F)[C@@H]1O

nearest known ligand 0.52

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 1/20 0.51
SLC28A2 O43868 1/20 0.51
SLC29A1 Q99808 1/20 0.51
SLC28A3 Q9HAS3 1/20 0.51
P2RY2 P41231 9/20 0.46
P2RY6 Q15077 7/20 0.43
P2RY4 P51582 3/20 0.42
P2RY14 Q15391 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4390144 1.00 SLC28A1 (0.51) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL13274081 0.89 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL800388 0.89 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL800357 0.89 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL4637211 0.89 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL5052768 0.89 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL13274080 0.89 SLC28A1 (0.50) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL4950152 0.88 SLC28A1 (0.61) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL25752456 0.87 SLC28A1 (0.51) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
SCHEMBL7649072 0.83 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629447-B2 Dideoxynucleoside derivatives WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-12-08 US disclosed
US-20080064868-A1 Novel Dideoxynucleoside Derivatives WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064868-A1 Novel Dideoxynucleoside Derivatives DNA2, DDX20, DNASE1 SLC28A1 373/4885SLC28A2 334/4885SLC29A1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.